多替拉韦维持单药治疗HIV-1病毒学失败患者的耐药动态
基于DOMONO随机试验(NCT02401828),对10例多替拉韦维持单药治疗病毒学失败患者进行Sanger测序,失败时中位HIV RNA载量为3490 copies/mL,4例检出INSTI耐药相关突变,4例未检出,2例测序失败,1例出现3'-PPT突变。
要点
- 失败时中位HIV RNA载量3490 copies/mL(IQR 1440-4990 copies/mL)。
- 10例中4例检出INSTI-RAMs(S230R、R263K、N155H、E92Q+N155H),4例未检出,2例测序失败。
- 1例出现高度保守3'-PPT突变,3'-LTR末端碱基未见改变。
核心结论
- 耐药遗传屏障过低,不足以支持多替拉韦维持单药治疗,因为单一INSTI-RAM即可导致病毒学失败。
- 至病毒学失败时间差异大,提示含单一INSTI-RAM的既存原病毒随机再激活是失败机制。
- 3'-PPT改变提示体内存在新的多替拉韦耐药机制。
研究设计与样本
- 基于随机DOMONO研究(NCT02401828),从10例病毒学失败患者采集cART开始前及失败时血浆样本,用Sanger测序分析整合酶、3'-LTR的5'端碱基及3'-PPT。
主要发现
- 病毒学失败时中位HIV RNA载量为3490 copies/mL(IQR 1440-4990 copies/mL)。
- 4例检出INSTI-RAMs(S230R、R263K、N155H、E92Q+N155H),4例未检出INSTI-RAMs,2例整合酶基因测序未成功。
- 至病毒学失败时间为4周至72周。
- 1例出现高度保守3'-PPT突变,3'-LTR末端碱基未见改变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A high genetic barrier to resistance to the integrase strand transfer inhibitor (INSTI) dolutegravir has been reported in vitro and in vivo. We describe the dynamics of INSTI resistance-associated mutations (INSTI-RAMs) and mutations in the 3'-polypurine tract (3'-PPT) in relation to virologic failure (VF) observed in the randomized Dolutegravir as Maintenance Monotherapy for HIV-1 study (DOMONO, NCT02401828). METHODS: From 10 patients with VF, plasma samples were collected before the start of cART and during VF, and were used to generate Sanger sequences of integrase, the 5' terminal bases of the 3' long terminal repeat (LTR), and the 3'-PPT. RESULTS: Median human immunodeficiency virus RNA load at VF was 3490 copies/mL (interquartile range 1440-4990 copies/mL). INSTI-RAMs (S230R, R263K, N155H, and E92Q+N155H) were detected in 4 patients, no INSTI-RAMs were detected in 4 patients, and sequencing of the integrase gene was unsuccessful in 2 patients. The time to VF ranged from 4 weeks to 72 weeks. In 1 patient, mutations developed in the highly conserved 3'-PPT. No changes in the terminal bases of the 3'-LTR were observed. CONCLUSIONS: The genetic barrier to resistance is too low to justify dolutegravir maintenance monotherapy because single INSTI-RAMs are sufficient to cause VF. The large variation in time to VF suggests that stochastic reactivation of a preexisting provirus containing a single INSTI-RAM is the mechanism for failure. Changes in the 3'-PPT point to a new dolutegravir resistance mechanism in vivo. CLINICAL TRIALS REGISTRATION: NCT02401828.
引用
- Wijting IEA, Lungu C, Rijnders BJA, et al. HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. J Infect Dis. 2018. PMID: 29617822. doi:10.1093/infdis/jiy176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。